Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, with reference to the statement by Peter Clark of NHS England that cancer drugs on the list of treatments which are approved for funding must be re-evaluated, reported in The Guardian's article of 28 August 2014 entitled 'Cancer Drugs Fund gets £160 million more for innovative treatments' through what process cancer drugs will be re-evaluated; and whether cancer drugs will be subject to assessments of their cost-effectiveness.

NHS England has oversight of the Cancer Drugs Fund.

NHS England has advised that work is currently underway to determine the process for reviewing drugs on its national list of cohort policies and on how best to assess costs in relation to clinical benefit delivered.